AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30218626
Drug: rasagiline 0.5
RxNorm normalized name: rasagiline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rasagiline 0.5 mg
Trial: 30218626
Drug: rasagiline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rasagiline 1.0 mg
Trial: 30218626
Drug: rasagiline 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rasagiline 2.0 mg
Trial: 30218626
Drug: rasagiline 0.5
RxNorm normalized name: rasagiline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rasagiline 0.5 mg (multiple administration)
Trial: 28419317
Drug: High-Frequency Lanreotide
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-Frequency Lanreotide Autogel (120 mg/21 days)
Trial: 28419317
Drug: High-Dose Lanreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Dose Lanreotide Autogel (180 mg/28 days)
Trial: 26510186
Drug: Low glucose
RxNorm normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glucose degradation product (GDP) solution
Trial: 26510186
Drug: Conventional solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional solutions
Trial: 21591985
Drug: NUTRIOSE(®) supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE(®) supplementation (17 g twice daily for 12 weeks)
Trial: 17075115
Drug: Surgery followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surgery followed by 6 months of systemic adjuvant chemotherapy with fluorouracil and folinic acid
Trial: 10326742
Drug: Dirithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirithromycin (500 mg once daily for 5 days)
Trial: 9950107
Drug: Azithromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (500 mg once daily for 3 days)
Trial: 8601548
Drug: Divalproex 20
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex 20 mg/kg/day
Trial: 28605827
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral naltrexone plus a 30-day prescription
Trial: 21895923
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine followed by PCA (Group P)
Trial: 21895923
Drug: DO(2) I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DO(2) I < 400 ml/min/m(2)
Trial: 21895923
Drug: DO(2) I
RxNorm normalized name: IOBENGUANE I 123
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DO(2) I > 400 ml/min/m(2)
Trial: 19255176
Drug: Initial infiltration
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial infiltration of 1.8 mL of 2 percent lidocaine with 1:100,000 epinephrine plus repeated infiltration of the same anesthetic 30 minutes later
Trial: 19255176
Drug: Initial infiltration
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial infiltration of 1.8 mL of 2 percent lidocaine with 1:100,000 epinephrine plus mock repeated infiltration 30 minutes later
Trial: 12172084
Drug: triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triple therapy
Trial: 16870008
Drug: Fish oil/5‐MTHF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil/5‐MTHF treatment
Trial: 12771974
Drug: Chitosan (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan (1.2 g per day)
Trial: 6437842
Drug: Glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5 mg) with acarbose (3 X 100 mg daily)
Trial: 27405061
Drug: 200-mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg group (50-mg intravenous bolus every 6 h during 7 days)
Trial: 27405061
Drug: 300-mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg group (100-mg initial bolus followed by continuous infusion of 300 mg daily for 5 days)
Trial: 27405061
Drug: 300-mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300-mg group
Trial: 27405061
Drug: 200-mg group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg group
Trial: 23225445
Drug: Menatetrenone (MNT)
RxNorm normalized name: menatetrenone
DrugBank: Menatetrenone (DB12148)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (MNT) 45 mg daily
Trial: 16301236
Drug: MgSO4 30
RxNorm normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MgSO4 30 mg/kg
Trial: 2719894
Drug: Amitriptyline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (150 mg daily for 13 days)
Trial: 2719894
Drug: Femoxetine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Femoxetine (600 mg daily for 13 days)
Trial: 28211816
Drug: Levodopa-carbidopa intestinal
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa-carbidopa intestinal gel (LCIG) infusion
Trial: 28211816
Drug: Immediate-release oral
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release oral levodopa-carbidopa (LC-oral) treatment
Trial: 23237136
Drug: Prasugrel 5
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5 mg/d
Trial: 24913197
Drug: Clopidogrel 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 150 mg/d
Trial: 19371823
Drug: Clopidogrel therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel therapy beyond 6 months after index PCI
Trial: 19371823
Drug: Lack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack of aspirin
Trial: 11521725
Drug: trastuzumab (single-agent)
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: trastuzumab (single-agent)
Trial: 11521725
Drug: trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab plus paclitaxel (weekly)
Trial: 11521725
Drug: aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aromatase inhibitor ± trastuzumab
Trial: 17050503
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg losartan
Trial: 2957859
Drug: Other infusion
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other infusion solutions
Trial: 30634208
Drug: Xinfeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng Capsule (XFC) 0.5 g/pill, 3 pills each time, 3 times per day for 90 days
Trial: 19757017
Drug: 0.1% UC781
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% UC781 gel
Trial: 10363611
Drug: Prednisolone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (2 x 250 mg)
Trial: 10363611
Drug: Heparin-coated circuits
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated circuits ('Bioline' by Jostra)
Trial: 7669486
Drug: Remoxipride 50
RxNorm normalized name: remoxipride
DrugBank: Remoxipride (DB00409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remoxipride 50 mg
Trial: 7669486
Drug: Thyrotropin release
RxNorm normalized name: Thyrotropin
DrugBank: Thyrotropin (DB15263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrotropin release hormone (TRH)
Trial: 340945
Drug: terbutaline 2.5
RxNorm normalized name: terbutaline 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline 2.5 mg
Trial: 340945
Drug: aminophylline 200
RxNorm normalized name: aminophylline 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aminophylline 200 mg
Trial: 340945
Drug: terbutaline 2.5
RxNorm normalized name: terbutaline 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbutaline 2.5 mg plus aminophylline 200 mg
Trial: 21886067
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bid, Amoxicillin 1 g bid, Clarithromycin 500 mg bid (LAC) for 14 days
Trial: 21886067
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bid, Levofloxacin 500 mg bid, Amoxicillin 1 g bid (OLA) for 7 days
Trial: 12567694
Drug: Benflumetol tablet
DrugBank: Lumefantrine (DB06708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benflumetol tablet
Trial: 12567694
Drug: Benflumetol capsule
DrugBank: Lumefantrine (DB06708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benflumetol capsule
Trial: 25524333
Drug: Prasugrel pre-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel pre-treatment (30-mg loading dose)
Trial: 15359898
Drug: Pravastatin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin therapy
Trial: 11207518
Drug: 5-day RACM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day RACM regimen (rabeprazole 20 mg b.d., amoxicillin 750 mg b.d., clarithromycin 200 mg b.d., metronidazole 250 mg b.d.)
Trial: 8341175
Drug: Carbimazole 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole 15 mg twice daily (group 2)
Trial: 8341175
Drug: Carbimazole 10
RxNorm normalized name: carbimazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole 10 mg thrice daily (group 3)
Trial: 9060552
Drug: no initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no initial treatment
Trial: 17363538
Drug: Indisulam (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indisulam (700 mg/m2 as a single i.v. dose on day one)
Trial: 17363538
Drug: Indisulam (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indisulam (130 mg/m2 given on days 1 to 5 as a daily infusion)
Trial: 17363538
Drug: Indisulam (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indisulam (both treatment schedules)
Trial: 11132373
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg elemental iron twice-weekly for 12 months
Trial: 16645456
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia
Trial: 18485457
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (Control)
Trial: 20865580
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received standard anesthetic protocol and IV morphine via PCA
Trial: 16642606
Drug: Spray inhalation
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray inhalation of western medicine, once daily for 7 days.
Trial: 23055414
Drug: Paroxetine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-40 mg) with mirtazapine
Trial: 23055414
Drug: Paroxetine (20-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20-40 mg) with placebo
Trial: 16935794
Drug: 5% Vitreoscilla
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Vitreoscilla filiformis (V.f.) extract-containing ointment
Trial: 18390083
Drug: Oral medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medroxyprogesterone acetate (5 mg daily)
Trial: 29234748
Drug: Calcium‐incorporated titanium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium‐incorporated titanium implants (Xpeed)
Trial: 26355169
Drug: Control resorbable
RxNorm normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control resorbable blasted media (RBM) implants
Trial: 21673005
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg on alternate days
Trial: 22090661
Drug: Prediction-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prediction-based treatment using the newly developed model
Trial: 22090661
Drug: Selective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective treatment of women >65 years of age
Trial: 22090661
Drug: Aspirin treatment
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin treatment strategy
Trial: 19673814
Drug: music-supported therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: music-supported therapy
Trial: 30834280
Drug: No additional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No additional therapy (control group)
Trial: 15057737
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg/day for 56 days
Trial: 9673781
Drug: Inhaled HFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled HFA BDP (0.2 or 0.8 mg)
Trial: 2502168
Drug: Ketamine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 1.5 mg kg‐1
Trial: 28709470
Drug: Cognitive Bias
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Bias Modification (CBM) training with oxytocin administration
Trial: 28709470
Drug: Placebo training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo training with oxytocin administration
Trial: 22196062
Drug: 6% sevoflurane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% sevoflurane with 4 L/min O₂ for 3 minutes
Trial: 22196062
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-sevoflurane) with 4 L/min O₂ alone
Trial: 18676056
Drug: 20Gy of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20Gy of radiation in 2 weeks followed by two courses of chemotherapy (paclitaxel 180mg/m², cisplatin 45mg/m², ifosfamide 1000mg/m²)
Trial: 18676056
Drug: Treatment related
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment related morbidity
Trial: 17519056
Drug: Same-room treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-room treatment
Trial: 15189943
Drug: Drotrecogin alfa
RxNorm normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drotrecogin alfa (activated) 24 micro g/kg/h, continuous IV infusion for 96 ± 1 h
Trial: 11440912
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein intake (0.3 g/kg/day) with [(15)N]Spirulina platensis
Trial: 9059200
Drug: Morphine 10
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 10 mg
Trial: 7973475
Drug: MTX 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX 7.5 mg/week and CHLO 250 mg/day
Trial: 18716531
Drug: Regular oral
RxNorm normalized name: infant formula,regular ORAL PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular oral analgesics
Trial: 29676980
Drug: 10% HP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% HP gel (low viscosity)
Trial: 29676980
Drug: 10% HP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% HP gel (medium viscosity)
Trial: 29676980
Drug: 10% HP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% HP gel (high viscosity)
Trial: 11949768
Drug: Temazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (15 mg)
Trial: 10463516
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) 500 mg/d
Trial: 10463516
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine (ddI) 750 mg/d
Trial: 10357377
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) monotherapy
Trial: 10463516
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ddI/ZDV
Trial: 10463516
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with zalcitabine/ZDV
Trial: 9035703
Drug: Tazarotene gel
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene gel applied once daily
Trial: 7201839
Drug: Dihydroergotoxine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotoxine (2 mg, three times a day)
Trial: 22257126
Drug: Fluoxetine (n=157)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (n=157)
Trial: 10859864
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml PCECV intradermally at two sites on days 0, 3, 7, and at one site on days 30 and 90
Trial: 10859864
Drug: Purified Vero
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified Vero cell rabies vaccine (PVRV) administered similarly to Group 1
Trial: 10859864
Drug: 1.0 ml
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 ml PCECV intramuscularly on days 0, 3, 7, 14, 30 and 90
Trial: 1279214
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg terazosin
Trial: 1279214
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg terazosin
Trial: 29713249
Drug: Placebo (gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gelatin capsules)
Trial: 26959502
Drug: Mobile unit
RxNorm normalized name: Chamaemelum nobile extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile unit laser photocoagulation treatment
Trial: 26959502
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to outpatient eye clinic for follow-up treatment
Trial: 22710865
Drug: Neopterin levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neopterin levels before induction chemotherapy (day 0) in patient group 1 (children with acute leukemia)
Trial: 2634902
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg i.v.)
Trial: 6786673
Drug: 0.25-0.5 microgram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25-0.5 microgram oral 1,25-dihydroxy vitamin D3
Trial: 28049262
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (110 mg BTPP) of black tea drink
Trial: 28049262
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (220 mg BTPP) of black tea drink
Trial: 28049262
Drug: Placebo drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drink (0 mg BTPP)
Trial: 25977992
Drug: Levobupivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.125% + sufentanil 0.75 μg/mL
Trial: 25977992
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% + sufentanil 0.75 μg/mL
Trial: 22796450
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy plus rectal insufflation of O(3)
Trial: 22796450
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy only
Trial: 17353246
Drug: Fosfomycin (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosfomycin (8 g)
Trial: 2407581
Drug: Highest quartile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest quartile of fasting insulin distribution
Trial: 31834660
Drug: Immediate periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate periodontal therapy (one‐stage scaling and root planning, amoxicillin 500 mg, metronidazole 400 mg, oral hygiene instructions)
Trial: 31834660
Drug: Delayed periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Delayed periodontal therapy (control group)
Trial: 12552210
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (100 microg)
Trial: 19517674
Drug: Both interventions
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both interventions (morphine and fentanyl)
Trial: 19087079
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral nifedipine tablet
Trial: 8203837
Drug: Sparfloxacin (SPX)
DrugBank: Sparfloxacin (DB01208)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sparfloxacin (SPX) 400 mg on day 1 and 200 mg on days 2 to 8
Trial: 3300178
Drug: Trimethoprim 300
RxNorm normalized name: trimethoprim 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim 300 mg daily
Trial: 11979239
Drug: Large-volume epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Large-volume epinephrine injection (13-20 mL)
Trial: 11979239
Drug: Small-volume epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Small-volume epinephrine injection (5-10 mL)